Completed NA INTERVENTIONAL 2-arm NCT00822354

Tadalafil for the Treatment of Raynaud's

Tadalafil for the Treatment of Secondary Raynaud's Phenomenon

Sponsor: Eli Lilly and Company

Conditions Raynaud

Interventions Tadalafil

Updated 7 times since 2017 Last updated: Dec 2, 2014 Started: Sep 30, 2008 Primary completion: Feb 28, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Raynaud and is currently completed. Eli Lilly and Company leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States